

BioInvent to Participate in Upcoming Investor Conferences

Lund, Sweden – April 1, 2025 – BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that during April, the Company management team will participate in the following upcoming investor conferences:

Van Lanschot Kempen Life Sciences Conference

Format: One-on-one meetings

Date: April 2

Location: Amsterdam, The Netherlands

Stifel Virtual Targeted Oncology Forum

Format: Corporate presentation and one-on-one meetings

Date: April 8-9. Corporate presentation April 9 at 11:30 am EDT (Track 2)

Location: Virtual

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:

Cecilia Hofvander, VP Investor Relations

Phone: +46 (0)46 286 85 50

Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)

Co. Reg. No.: 556537-7263

Visiting address: Ideongatan 1

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

www.bioinvent.com

Press Release
01 April 2025 11:00:00 CEST



Attachments

[BioInvent to Participate in Upcoming Investor Conferences](#)